Revenue has been lumpy, swinging between $2.1M and $8.9M over ten quarters, while R&D of $12.9M in 2026Q2 and a -100.7% operating margin indicate that the cost base remains far too large for the current revenue run-rate.
ProQR Therapeutics N.V. (PRQR) annual income statement — 13-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 |
|---|
| Sales/Revenue | 18.57M | 15.28M | 18.91M | 6.51M | 3.59M | 1.33M | 1.03M | 1.93M | 4.94M | -1.53M | 2.28M | 9.41M | 313K | 0 |
| Revenue Growth % | 12.66% | -19.18% | 190.22% | 81.25% | 169.21% | 29.74% | -46.77% | -60.88% | 423.15% | -167% | -75.74% | 2905.43% | - | - |
| Cost of Goods Sold | 1.42M | 2.6M | 0 | 0 | 0 | 0 | 0 | 116.82M | 983.51K | 1M | 1.28M | 482.85K | 0 | 0 |
| COGS % of Revenue | - | 16.99% | - | - | - | - | - | 6043.61% | 19.91% | -65.49% | 56.16% | 5.13% | - | - |
| Gross Profit | 17.15M | 12.68M | 18.91M | 6.51M | 3.59M | 1.33M | 1.03M | -114.89M | 3.96M | -2.53M | 1M | 8.92M | 313K | 0 |
| Gross Margin % | 92.33% | 83.01% | 100% | 100% | 100% | 100% | 100% | -5943.61% | 80.09% | 165.49% | 43.84% | 94.87% | 100% | - |
| Gross Profit Growth % | - | -32.92% | 190.22% | 81.25% | 169.21% | 29.74% | 100.9% | -3003.1% | 256.4% | -352.93% | -88.79% | 2751.17% | - | - |
| Operating Expenses | 60.37M | 54.84M | 49.38M | 38.37M | 68.75M | 58.55M | 43.4M | 59.38M | 42.05M | 41.99M | 41.4M | 30.24M | 16.77M | 3.24M |
| OpEx % of Revenue | - | 358.92% | 261.18% | 589.09% | 1912.99% | 4385.39% | 4217.4% | 3071.81% | 851.12% | -2746.44% | 1814.24% | 321.44% | 5359.11% | - |
| Selling, General & Admin | 15.14M | 15.06M | 13.66M | 16.24M | 18.65M | 17.37M | 13.69M | 12.89M | 12.54M | 10.84M | 9.48M | 6.84M | 6.51M | 786K |
| SG&A % of Revenue | - | 98.57% | 72.26% | 249.25% | 518.95% | 1300.97% | 1329.93% | 666.68% | 253.79% | -708.96% | 415.34% | 72.68% | 2078.91% | - |
| Research & Development | 45.9M | 40.72M | 36.36M | 25.15M | 50.87M | 42.22M | 38.13M | 46.49M | 29.51M | 31.15M | 31.92M | 23.4M | 10.27M | 2.57M |
| R&D % of Revenue | - | 266.51% | 192.31% | 386.06% | 1415.33% | 3162.55% | 3706.03% | 2405.12% | 597.33% | -2037.48% | 1398.9% | 248.76% | 3280.19% | - |
| Other Operating Expenses | -670.07K | -941.13K | -640K | -3.01M | -765K | -1.04M | -8.42M | 1.93M | 5.76M | 1.5M | 1.83M | 3.23M | 0 | 0 |
| Operating Income | -43.22M | -42.15M | -30.47M | -31.86M | -65.16M | -57.21M | -42.37M | -57.45M | -36.29M | -40.5M | -39.57M | -27M | -16.46M | -3.24M |
| Operating Margin % | -232.71% | -275.91% | -161.18% | -489.09% | -1812.99% | -4285.39% | -4117.4% | -2971.81% | -734.53% | 2648.66% | -1734.14% | -287.05% | -5259.11% | - |
| Operating Income Growth % | - | -38.34% | 4.35% | 51.11% | -13.89% | -35.03% | 26.25% | -58.28% | 10.38% | -2.34% | -46.55% | -64.04% | -408.21% | - |
| EBITDA | -40.46M | -39.45M | -27.71M | -29.35M | -62.64M | -54.88M | -40.01M | -55.39M | -35.3M | -39.43M | -38.33M | -26.52M | -16.34M | -3.21M |
| EBITDA Margin % | -217.84% | -258.22% | -146.58% | -450.51% | -1742.85% | -4110.94% | -3888.54% | -2865.65% | -714.45% | 2579.01% | -1679.58% | -281.95% | -5218.85% | - |
| EBITDA Growth % | -3.35% | -42.37% | 5.57% | 53.15% | -14.13% | -37.16% | 27.77% | -56.92% | 10.48% | -2.88% | -44.51% | -62.37% | -408.09% | - |
| D&A (Non-Cash Add-back) | 2.76M | 2.7M | 2.76M | 2.51M | 2.52M | 2.33M | 2.35M | 2.05M | 992K | 1.06M | 1.25M | 480K | 126K | 24K |
| EBIT | -40.46M | -39.63M | -26.88M | -26.61M | -58.98M | -57.28M | -50.79M | -172.35M | -36.27M | 0 | -37.21M | 36.8M | 21.37M | -3.21M |
| Net Interest Income | 697.22K | 1.37M | 2.17M | 1.39M | -5.02M | -3.4M | -1.73M | -681K | -1.6M | -3.77M | -68K | 5.78M | 4.07M | -14K |
| Interest Income | 697.22K | 2.24M | 3.25M | 2.59M | 106K | 5K | 313K | 402K | -792K | -3.17M | 470K | 6.17M | 4.33M | 24K |
| Interest Expense | 0 | 866.4K | 1.08M | 1.2M | 5.13M | 3.4M | 2.04M | 1.08M | 810K | 596K | 538K | 395K | 265K | 38K |
| Other Income/Expense | 847.34K | 1.65M | 2.51M | 4.05M | 1.05M | -3.47M | -4.12M | 117.65M | -792K | 850.31K | 470K | 6.17M | 4.33M | -14K |
| Pretax Income | -42.38M | -40.5M | -27.96M | -27.81M | -64.11M | -60.68M | -46.49M | -56.61M | -37.09M | -43.67M | -39.1M | -20.83M | -12.13M | -3.25M |
| Pretax Margin % | -228.15% | -265.09% | -147.9% | -426.97% | -1783.75% | -4545.47% | -4517.98% | -2928.82% | -750.56% | 2856.31% | -1713.54% | -221.45% | -3874.44% | - |
| Income Tax | 26.41K | 18.25K | -197K | -78K | 96K | 117K | 124K | 132K | 1K | 2K | 0 | 0 | 0 | 24K |
| Effective Tax Rate % | -0.06% | -0.05% | 0.7% | 0.28% | -0.15% | -0.19% | -0.27% | -0.23% | -0% | -0% | 0% | 0% | 0% | -0.74% |
| Net Income | -42.4M | -40.52M | -27.76M | -28.12M | -64.42M | -60.74M | -46.56M | -56.75M | -36.89M | -43.64M | -39.1M | -20.83M | -12.13M | -3.25M |
| Net Margin % | -228.29% | -265.21% | -146.86% | -431.67% | -1792.54% | -4549.81% | -4525.27% | -2935.64% | -746.69% | 2853.96% | -1713.54% | -221.45% | -3874.44% | - |
| Net Income Growth % | -6.88% | -45.95% | 1.27% | 56.35% | -6.07% | -30.44% | 17.94% | -53.81% | 15.45% | -11.59% | -87.71% | -71.78% | -272.79% | - |
| Net Income (Continuing) | -42.4M | -40.52M | -27.76M | -27.73M | -64.2M | -60.8M | -46.61M | -56.75M | -36.89M | -43.64M | -39.1M | -20.83M | -12.13M | -3.25M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | -409.82K | -686.87K | -666.83K | -556.76K | -262.92K | -45.63K | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.39 | -0.38 | -0.34 | -0.35 | -0.91 | -0.96 | -0.93 | -1.38 | -1.08 | -1.72 | -1.67 | -0.89 | -0.55 | -0.15 |
| EPS Growth % | 7.8% | -11.76% | 2.86% | 61.54% | 5.21% | -3.23% | 32.61% | -27.78% | 37.21% | -2.99% | -87.64% | -61.82% | -266.67% | - |
| EPS (Basic) | - | -0.38 | -0.34 | -0.35 | -0.91 | -0.96 | -0.93 | -1.38 | -1.08 | -1.72 | -1.67 | -0.89 | -0.55 | -0.15 |
| Diluted Shares Outstanding | 109.96M | 105.33M | 81.67M | 81.01M | 71.64M | 64.18M | 50.06M | 41.04M | 34.05M | 25.37M | 23.35M | 23.34M | 22.15M | 22.21M |
| Basic Shares Outstanding | 109.96M | 105.33M | 81.67M | 81.01M | 71.64M | 64.18M | 50.06M | 41.04M | 34.05M | 25.37M | 23.35M | 23.34M | 22.15M | 22.21M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying PRQR stock.
For fiscal year 2025, ProQR Therapeutics N.V. (PRQR) reported total revenue of $15.3M.
ProQR Therapeutics N.V. (PRQR) reported a net loss of $40.5M for the fiscal year ending 2025.
ProQR Therapeutics N.V. (PRQR) reported an operating income of $-42.2M, resulting in an operating profit margin of -275.9%. This margin reflects the operational efficiency of the business before interest and taxes.
ProQR Therapeutics N.V. (PRQR) generated $12.7M in gross profit for the year, representing a gross profit margin of 83.0%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Persistent operating losses dominate
Lumpy Collaboration Revenue Without Clear Compounding
Based on reported quarterly figures, PRQR's revenue swung between $2.1M and $8.9M over ten quarters, with the latest quarter's 133.3% year-over-year jump appearing to reflect irregular licensing or collaboration recognition rather than durable commercial demand.
The revenue series shows no consistent upward trajectory, with several quarters near $3-4M interspersed with sharp spikes. This pattern is typical of milestone-driven biotech income rather than product sales. Investors should monitor whether the 2026Q2 spike recurs, since a single-quarter jump does not establish growth durability.
Gross Margin Reflects Revenue Mix Not Pricing Power
As reported in the income statement, PRQR's gross margin oscillated between 65.9% and 100.0%, with COGS appearing only in 2026 quarters, suggesting a shift in revenue composition rather than a structural change in pricing power.
Gross margin prints of 100% for most of the period reflect the absence of reported cost of goods rather than an efficient cost base. The emergence of COGS in 2026 coincides with the revenue spike, which may indicate a product or service stream with associated direct costs. Peer comparison is limited, as margin profiles across the group vary widely by business model.
R&D Dominates a Persistently Loss-Making Cost Base
Based on the reported income statement, PRQR's R&D expense ran between $7.0M and $12.9M per quarter, consuming well over twice the company's revenue in most periods and driving operating losses throughout the decade.
R&D is the principal cost line, and its level relative to revenue indicates the company remains in a development-stage cost structure. SG&A held relatively steady near $3-5M, implying limited overhead scaling. Whether R&D intensity declines as programs advance is the central question, and the data do not yet show that trend.
Operating Losses Widen Despite Stable Overhead
As reported in financial statements, PRQR's operating loss ranged from $3.6M to $13.9M, and the operating margin remained deeply negative, indicating that the revenue base has not yet scaled to offset a largely fixed development spend.
Operating leverage is currently negative because cost growth in R&D outpaces the irregular revenue line. The most recent quarter shows operating loss of $9.0M against $8.9M of revenue, reflecting how little of the cost base revenue currently covers. Positive operating leverage would require revenue to become recurring at a scale that absorbs R&D.
Net Loss Tracks Operations with Minimal Adjustments
Based on reported figures, PRQR's net loss closely tracks operating loss, with EPS of -$0.08 to -$0.13 and stock-based compensation of $0.6M to $1.4M per quarter, suggesting limited non-operating distortion in reported earnings.
Net income sits close to operating income in most quarters, indicating few material non-operating items affecting the bottom line. Stock-based compensation rose in 2026 to $1.4M, which warrants monitoring as it adds to economic cost. Earnings quality is less of a concern than the underlying operating loss itself.
Revenue Spike May Not Survive Scrutiny
Based on reported figures, the 2026Q2 revenue of $8.9M against a $2.1M prior quarter may prove non-recurring, and a bear case would argue that operating losses of $9.0M persist regardless of the headline jump.
Short-side analysis would focus on whether the latest revenue spike reflects one-time milestone recognition rather than sustainable demand, since the prior eight quarters averaged well below this level. Even with the spike, operating expenses of roughly $12.9M in R&D alone imply that a single strong quarter does not close the funding gap. Investors should monitor whether subsequent quarters sustain revenue near this level before extrapolating growth.